The American Heart Association and American Stroke Association released updated 2026 guidelines for the early management of acute ischemic stroke [1].
These updates integrate a decade of medical advances to expand access to life-saving therapies and provide the first evidence-based guidance for treating children who suffer strokes [2].
Neurologist Elisabeth Marsh of Johns Hopkins Medicine presented the highlights of the new standards, which were published online on Jan. 26, 2026 [1, 3]. The guidelines now endorse the use of mobile stroke units and refined triage protocols for emergency medical services to accelerate care delivery [1, 4].
Regarding medication, the new standards expand the use of tenecteplase alongside alteplase. Both thrombolytic treatments are now endorsed for use within a 4.5-hour window [3, 5].
"The new guideline endorses the use of either alteplase or tenecteplase in the 4.5-hour thrombolytic treatment window," the AHA/ASA said in a press release [3].
Beyond medication, the 2026 guidelines broaden the eligibility criteria for endovascular thrombectomy, a procedure to remove blood clots from the brain [4]. The update also establishes the first formal recommendations for the management of pediatric acute ischemic stroke, filling a critical gap in previous clinical guidance [2, 4].
Shyam Prabhakaran, MD, noted the impact of these changes on clinical practice. "This update brings the most important advances in stroke care from the last decade directly into practice," Prabhakaran said [6].
“These updates integrate a decade of medical advances to expand access to life-saving therapies.”
The shift toward mobile stroke units and the inclusion of pediatric guidelines represent a move toward decentralized, specialized care. By expanding the types of eligible patients for thrombectomy and thrombolytics, the medical community is attempting to reduce long-term disability by widening the window of effective intervention.
